Last updated: July 9, 2026
What patents did Wyeth assert against Sun in 1:16-cv-01305?
Wyeth asserted U.S. patents listed in the Orange Book for the relevant branded product at issue in the district court case captioned Wyeth LLC v. Sun Pharmaceutical Industries, Inc., 1:16-cv-01305. The litigation is a typical Hatch-Waxman framework in which the patentee alleges that Sun’s proposed ANDA drug infringes one or more Orange Book patents and that Sun’s Paragraph IV notice is invalid.
Which Orange Book-listed patents were the basis of the claims?
The record for 1:16-cv-01305 is organized around the Orange Book patent listings for Wyeth’s product and the ANDA submission addressed in the Paragraph IV notice. The asserted patents map to one or more of the following categories:
- Drug substance or composition of matter patents
- Formulation patents (e.g., dosage-form compositions)
- Method-of-use patents (e.g., therapeutic regimens in the labeled indication)
- Manufacturing process patents (less common but possible depending on the Orange Book listings)
How does Wyeth’s infringement theory typically break down in this case type?
In Paragraph IV cases like this, infringement arguments usually align with claim chart mapping:
- Claim element-by-element comparison of the ANDA product’s claimed attributes (composition, formulation parameters, or use instructions)
- Technical parity positions on active ingredient identity, impurities/specs, and dosage form
- Expert testimony on whether Sun’s proposed drug falls within the asserted claim limitations
What was Sun’s invalidity and non-infringement defense strategy in 1:16-cv-01305?
Sun’s defenses in Hatch-Waxman patent actions commonly cover:
- Non-infringement (no product falls within claim limits)
- Invalidity (anticipation, obviousness, lack of enablement, indefiniteness, or written description issues)
- Exhaustion or other legal defenses depending on the patent type and prosecution history
- Design-around arguments when formulation or method claims are asserted
Did Sun argue generic design-around or claim construction failures?
In disputes focused on formulation or method-of-use patents, Sun often argues:
- Proposed formulation or labeling does not meet claim features (e.g., concentration ranges, excipient selections, release profiles)
- Labeling and proposed use instructions do not induce infringement or do not directly perform the claimed method (in method-of-use cases)
- Narrow claim construction based on prosecution history estoppel or intrinsic evidence
What did the court decide in Wyeth LLC v. Sun (1:16-cv-01305), and what issues were dispositive?
Wyeth v. Sun follows the typical decision path in D. Del. Paragraph IV actions:
- Claim construction orders that narrow or broaden asserted claim terms
- Dispositive motions on infringement and invalidity
- Settlement or final judgment depending on the stage and rulings
Which ruling drives exclusivity and launch timelines?
The controlling question for generic entry is whether any asserted patent is:
- Valid and infringed, or
- Invalid (so exclusivity expires for purposes of the asserted claims) and/or
- Not infringed (so Sun can potentially launch if remaining patents do not block entry)
What is the practical effect of the ruling on generic entry risk?
For business planning, the key is:
- Whether the asserted claims survive at claim construction and summary judgment
- Whether Sun avoids a permanent injunction and whether remaining patents bar entry
- Whether there is an agreed entry date via settlement
When does Sun’s Paragraph IV notice convert into real launch risk for this case?
Paragraph IV litigation controls launch through the 30-month stay and, after that, the ability to launch subject to patent injunction risk.
How does the 30-month stay apply in 1:16-cv-01305?
The timeline hinges on:
- ANDA submission and Paragraph IV certification date
- The filing date of the infringement suit (the stay starts based on the statutory mechanics once a suit is filed within the relevant window)
- Any subsequent court orders that change practical exclusivity
What happens if the case ends before 30 months?
If Wyeth’s claims fail early, Sun’s launch risk decreases materially:
- Non-infringement or invalidity findings can eliminate injunction risk on the asserted patents
- Remaining unasserted or uninvalidated patents can still block launch, depending on Orange Book status
Which settlements or injunctions affected market entry in Wyeth LLC v. Sun?
Settlement is common in Hatch-Waxman cases when:
- Claim construction narrows claims and undercuts the patentee’s infringement case
- Invalidity theories show strong anticipation/obviousness risk
- Both sides weigh the cost of trial and appeals
Did the case end in a negotiated resolution?
The case posture in 1:16-cv-01305 is consistent with a Hatch-Waxman litigation where resolution can occur via:
- Final judgment after dispositive rulings
- Consent judgment reflecting a settlement
- Stipulations tied to entry dates
What is the Orange Book status of Wyeth’s patents in this dispute?
Orange Book status governs:
- Which patents are eligible for Paragraph IV certification
- Whether Sun can trigger a 30-month stay
- How long exclusivity persists if patents are not invalidated or designed around
What Orange Book entries typically exist for this product class?
Orange Book listings often include:
- Primary composition patents
- Secondary formulation or dosage form patents
- Method-of-use patents if the branded label supports it
How does Orange Book timing interact with the litigation result?
If Wyeth’s Orange Book patents are:
- Held valid and infringed: generic launch is blocked or enjoined
- Invalidated: Sun’s ability to launch depends on remaining Orange Book patents and any other restraints
- Not infringed: launch risk decreases, but injunctions on other asserted patents still matter
How strong is Wyeth’s patent estate in this litigation compared with Sun’s generic risk?
In Hatch-Waxman actions, “strength” is best assessed by:
- The number of asserted patents
- Claim scope breadth versus foreseeable generic design-arounds
- Anticipation/obviousness exposure based on prior art density
- How claim construction aligns with the claimed ANDA product attributes
What to look for in the docket to gauge strength
Business-relevant signals include:
- Claim construction outcomes that keep key limitations intact for Wyeth
- Court denial or partial grant of summary judgment on infringement
- Treatment of invalidity theories at the motion stage
What generic entry risks exist for Sun if Wyeth prevailed (or lost) in 1:16-cv-01305?
Entry risk splits into:
- Patent injunction risk: whether an injunction blocks launch
- Design-around risk: whether Sun can modify formulation or labeling
- Appeal risk: whether a decision can be appealed with stayed effects
If Wyeth prevailed on validity and infringement
Sun’s planned launch is typically delayed:
- Until expiration or invalidation of the relevant patents
- Or until settlement provides an agreed launch date
If Sun prevailed on invalidity or non-infringement
Launch becomes feasible once:
- Court orders allow it
- Any remaining asserted patents do not block entry
- Post-decision appeal does not maintain effective injunctive relief
How does this case fit into broader patent litigation trends for generics vs. branded originators?
Wyeth v. Sun is part of a recurring pattern in D. Del. and Hatch-Waxman:
- Orange Book listing drives Paragraph IV notice structure
- Claim construction can determine whether infringement is plausible without a trial
- Invalidity arguments often pivot on enablement and obviousness, plus prior-art overlaps
What matters most for litigation strategy and licensing leverage
- If multiple patents are asserted, even one narrow remaining patent can block full launch
- If claims are method-of-use, labeling changes can shift risk
- If formulation claims are broad, design-around is harder
What is the regulatory status angle: ANDA pathway, FDA approvals, and entry timing?
The regulatory aspect is that:
- A Paragraph IV certification links litigation to FDA approval/launch timing
- FDA does not decide patent issues, but it controls procedural milestones
How the litigation outcome affects FDA commercialization
- Even with FDA approval, an injunction can prevent market entry
- A settlement or final invalidity ruling can unlock entry
- The controlling factor is whether the relevant patents remain enforceable and infringed after the court’s decisions
Key case metadata (for docket and business tracking)
| Field |
Value |
| Case name |
Wyeth LLC v. Sun Pharmaceutical Industries, Inc. |
| Docket number |
1:16-cv-01305 |
| Court |
U.S. District Court for the District of Delaware |
| Litigation type |
Hatch-Waxman patent infringement action based on Paragraph IV ANDA certification |
| Parties |
Patentee: Wyeth LLC; ANDA filer: Sun Pharmaceutical Industries, Inc. |
Key Takeaways
- The dispute is a Paragraph IV Hatch-Waxman action where Orange Book-listed patents drive the asserted claims and the generic entry stay mechanics.
- Business impact is determined by claim construction and any dispositive rulings on infringement and invalidity, which control whether Sun can launch and on what date.
- Settlement outcomes, if reached, typically translate into entry timing commitments and scope restrictions on the generic.
- Orange Book status remains the single best “gatekeeper” for whether Sun’s ANDA is free to commercialize without injunction risk.
FAQs
1) What does a Paragraph IV certification mean in Wyeth v. Sun (1:16-cv-01305)?
A Paragraph IV certification alleges that the Orange Book patents are not infringed, invalid, or will not be infringed by the proposed ANDA product.
2) How do claim construction decisions usually affect generic entry in D. Del. Hatch-Waxman cases?
They narrow or broaden key claim limitations, often determining whether the ANDA product plausibly infringes and whether invalidity arguments target the correct interpretation.
3) Does FDA approval automatically allow launch if a patent case is still pending?
No. FDA approval does not override an injunction or unresolved patent infringement risk tied to enforceable Orange Book patents.
4) Can a generic avoid infringement by changing formulation or labeling?
In many cases, yes. Formulation changes can avoid composition/formulation limitations, while method-of-use cases can be affected by labeling scope, though courts evaluate whether the change genuinely avoids claimed limitations.
5) What is the main determinant of exclusivity timeline in Paragraph IV litigation?
Whether asserted patents survive and remain enforceable (valid and infringed) versus being invalidated or found not infringed, which controls injunction risk and practical launch timing.
References
- Wyeth LLC v. Sun Pharmaceutical Industries, Inc., No. 1:16-cv-01305 (D. Del.).
